Although there has been much success in identifying genetic variants associated with common diseases using genome-wide association studies (GWAS) 1 , it has been difficult to demonstrate which variants are causal and what role they have in disease. Moreover, the modest contribution that these variants make to disease risk has raised questions regarding their medical relevance 2 . Here we have investigated a single nucleotide polymorphism (SNP) in the TNFRSF1A gene, that encodes tumour necrosis factor receptor 1 (TNFR1), which was discovered through GWAS to be associated with multiple sclerosis (MS) 3, 4 , but not with other autoimmune conditions such as rheumatoid arthritis 5 , psoriasis 6 and Crohn's disease 7 . By analysing MS GWAS 3, 4 data in conjunction with the 1000 Genomes Project data 8 we provide genetic evidence that strongly implicates this SNP, rs1800693, as the causal variant in the TNFRSF1A region. We further substantiate this through functional studies showing that the MS risk allele directs expression of a novel, soluble form of TNFR1 that can block TNF. Importantly, TNF-blocking drugs can promote onset or exacerbation of MS [9] [10] [11] , but they have proven highly efficacious in the treatment of autoimmune diseases for which there is no association with rs1800693. This indicates that the clinical experience with these drugs parallels the disease association of rs1800693, and that the MS-associated TNFR1 variant mimics the effect of TNF-blocking drugs. Hence, our study demonstrates that clinical practice can be informed by comparing GWAS across common autoimmune diseases and by investigating the functional consequences of the disease-associated genetic variation.
The largest MS GWAS 4 reports rs1800693 as the most associated SNP in the TNFRSF1A region by over two orders of magnitude (odds ratio for risk allele 5 1.12 (1.11-1.14); P 5 4.1 3 10 214 ). To assess whether this SNP is mainly driving the association we examined the haplotype structure across the region in 379 individuals of European ancestry using whole-genome sequence from the 1000 Genomes Project 8 and we performed statistical imputation into a UK cohort of 1,853 MS patients and 5,174 controls 4 . Among genotyped SNPs the strongest signal is seen at rs1800693 and the variants in strongest association with this SNP were also genotyped in the study. Statistical imputation 12 revealed no other variant with stronger association to MS within the region, including the previously reported 3 nonsynonymous SNP rs4149584 ( Supplementary Fig. 1 ), and analysis of association after controlling for the effect of rs1800693 removed almost all of the signal (Fig. 1a ). These observations all support variation at rs1800693 as being primarily responsible for the MS association in the TNFRSF1A region.
To further substantiate the causality of rs1800693, we next sought to investigate the functional consequences of the variation at this SNP. As rs1800693 is proximal to the TNFRSF1A exon 6/intron 6 boundary, we proposed that it may influence splicing of TNFR1 exon 6 (ref. 13) . In an in vitro minigene splicing assay, only the risk 'G' allele resulted in skipping of exon 6 ( Fig. 1b ). In primary human immune cells we found that the presence of the risk allele correlated with increased expression of transcripts lacking exon 6, with the gene dosage effect observed being consistent with the genetic effect on disease risk ( Fig. 1c and Supplementary Fig. 2 ). Moreover, these transcripts are translated in the primary immune cells, as binding of polysomes to these transcripts demonstrated active translation ( Supplementary Fig. 3 ). As full-length TNFR1 (FL-TNFR1) expression did not vary in a genotype-dependent fashion ( Supplementary Figs 4 and 5 ), this indicates that the effect of rs1800693 may be specifically mediated by its influence on the generation of a functional protein isoform lacking exon 6 (D6-TNFR1), and we therefore investigated the properties of this molecule. TNFR1 exon 6 skipping results in a frameshift and a premature stop codon, which translates into a protein comprising only the aminoterminal 183 amino acids of FL-TNFR1, followed by a novel 45 amino acid sequence, as confirmed by tandem mass spectrometry (Supplementary Fig. 6 ). Consequently, D6-TNFR1 lacks the extracellular carboxy-terminal portion of the fourth cysteine-rich domain (CRD) of FL-TNFR1, the transmembrane domain, and the intracellular region that is essential for appropriate subcellular localization 14 . Whereas FL-TNFR1 localizes to the Golgi apparatus, D6-TNFR1 demonstrated a more diffuse intracellular distribution ( Fig. 2) , consistent with the absence of the Golgi-retention motif. Nevertheless, we observed partial subcellular colocalization of FL-TNFR1 and D6-TNFR1 (Supplementary Fig. 7 ), suggesting the potential for an interaction between the two isoforms. As D6-TNFR1 retains the pre-ligand assembly domain (PLAD/CRD1), required for TNFR1 trimerization at the cell surface 14, 15 , it could exert a functional effect on FL-TNFR1 by associating with it to form heteromers that would therefore have modified properties. To investigate the existence of such an interaction, we used FL-TNFR1 and D6-TNFR1 proteins fused at their carboxy termini with fluorescent or luciferase proteins in fluorescence and bioluminescence resonance energy transfer (FRET and BRET, respectively). This demonstrated that D6-TNFR1 associates neither with the full-length protein nor with itself ( Fig. 2c and Supplementary Fig. 8 ). Consistent with this and with the lack of transmembrane and cytoplasmic domains, D6-TNFR1 was not observed at the surface of transfected cells (Fig. 2d ). Hence, as D6-TNFR1 cannot interact with FL-TNFR1, it is unlikely to have a direct impact on the latter, intracellularly or at the cell surface.
To assess whether D6-TNFR1 has some intracellular function, regardless of its inability to associate with FL-TNFR1, we investigated TNFR1-mediated signalling in D6-TNFR1-transfected cells. As predicted by the absence of a death domain, which is necessary for both NF-kB-mediated signal transduction and apoptosis 14, 15 , no significant spontaneous NF-kB signalling or TNFR1-mediated apoptosis were observed upon D6-TNFR1 expression ( Supplementary Figs 9 and 10 ). However, D6-TNFR1 could potentially retain some intracellular activity by accumulating in the endoplasmic reticulum and evoking a stress response 15 . Nevertheless, there was no evidence for increased endoplasmic reticulum localization of D6-TNFR1 ( Fig. 2a, b ), or induction of the unfolded protein response in D6-TNFR1compared with FL-TNFR1-transfected cells ( Supplementary Fig. 11 ).
Given that no intracellular D6-TNFR1 activity was observed, and that this isoform has no transmembrane region and does not associate with FL-TNFR1, we proposed that D6-TNFR1 could exist as a soluble, functional molecule. Soluble TNFR1 generation has been previously described through exosomal release of full-length receptor and through metalloprotease-dependent cleavage of the FL-TNFR1 extracellular domain. Here, we demonstrate that skipping of exon 6 constitutes a novel mechanism of stable, soluble TNFR1 production: a higher level of soluble protein was found in supernatants of D6-TNFR1compared to FL-TNFR1-transfected cells ( Fig. 3a and Supplementary Fig. 12 ). Given the importance of determining the presence of D6-TNFR1 protein in primary human samples, an enzyme-linked immunosorbent assay (ELISA) for this molecule was established. This required the generation of an anti-D6-TNFR1-specific monoclonal antibody, using a human combinatorial antibody library in conjunction with phage display, as commercially available anti-TNFR1 antibodies are not specific for the splice isoform ( Supplementary Fig. 13 ). This ELISA allowed the detection of D6-TNFR1 in the sera of both healthy individuals 
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(range # 1.25-14.8 ng ml 21 ; n 5 12) and MS patients (range # 1.25-37.3 ng ml 21 ; n 5 13) ( Supplementary Fig. 14) . Furthermore, soluble D6-TNFR1 can bind to TNF, as shown in TNF pull-down assays using TNFR1-F c and D6-TNFR1-F c fusion proteins (Fig. 3b ). Using surface plasmon resonance the TNF binding ability of D6-TNFR1-F c was determined to be in the nanomolar range (K d 5 15.6 nM), indicating that the isoform has a high affinity for TNF ( Fig. 3c) . Critically, D6-TNFR1-F c proved to have a TNF antagonistic function as it can bind and neutralize the ability of TNF to signal through membrane-bound TNFR1 (Fig. 3d) , with the neutralization capacity of D6-TNFR1-F c being consistent with the surface plasmon resonance data. Our combined genetic and functional analyses strongly implicate rs1800693 as the causal SNP in the MS-associated TNFRSF1A region, with the risk allele directing an increased expression of D6-TNFR1. Because D6-TNFR1 protein is soluble and is capable of TNF antagonism, our evidence is consistent with the reported worsening of MS upon anti-TNF therapy 10, 11 . TNF antagonists were originally used in MS patients partly because increased levels of TNF were detected in both active lesions and cerebrospinal fluid from MS patients 16, 17 , and partly because of reports on animal models of MS where blockade of TNF prevented or delayed disease onset 18, 19 . However, opposing findings have also been obtained from animal studies 20 , and the paradoxical outcomes from these pre-clinical models, as well as the precise mechanism of TNF antagonist action, are unexplained but remain an active area of research 21, 22 .
TNF antagonists are largely beneficial in the treatment of other autoimmune conditions, including rheumatoid arthritis, psoriasis, Crohn's disease and ankylosing spondylitis 23 . In accordance with this, common genetic variants in the TNFRSF1A region have not been identified for these conditions [5] [6] [7] with the exception of ankylosing spondylitis 24 , that has a distinct association signal compared to MS ( Supplementary Fig. 15 ), indicating that D6-TNFR1 is unlikely to influence the pathology of these conditions. Notably, the MSassociated rs1800693 SNP is also associated with primary biliary cirrhosis 25 , but there is no controlled clinical study of TNF antagonists in this disease. Interestingly, side effects associated with the use of TNF antagonists in treating non-MS autoimmune diseases include clinical onset of MS and isolated demyelinating diseases, such as optic neuritis, which is often an early manifestation of MS 9, 26 . These side effects are relatively rare, indicating that they may only arise in individuals with a propensity for demyelinating disease that is unmasked upon treatment.
We have identified a disease-associated genetic variant that directs increased expression of a molecule that is analogous to drugs whose adverse effects can promote or exacerbate disease. This finding has broader implications. A criticism against the potential clinical value of GWAS findings has been the modest effect on disease risk conferred by most associated genetic variants 2 . However, this notion does not consider that drugs targeting the same pathways as the genetic variants are likely to have a larger functional impact and thus these variants may be clinically relevant 27 . We show that naturally occurring variation and therapeutic agents can have the same target, but their effect differs in magnitude: D6-TNFR1 and a TNF antagonist both neutralized TNF, but the antagonist had a greater ability to do so. Therefore, our result suggests that a signal of disease association for rs1800693 could be predictive of an adverse effect of TNF antagonist treatment. In conclusion, our study shows that, through genetic and functional followup investigations, GWAS can serve to directly inform therapeutic choice in the treatment of a common disease.
METHODS SUMMARY
Full descriptions of statistical analyses, minigene assays, transcript quantification, polysome profiling, mass spectrometry, ELISAs, and flow cytometric, confocal and biophysical analyses are available in the online version of the paper at www. nature.com/nature. 
RESEARCH LETTER
and IRDye 800CW goat-anti-mouse IgG secondary antibody, and visualized using an Odyssey Infrared Imaging System (LI-COR Biosciences). D6-TNFR1 measurement in human serum. Endogenous D6-TNFR1 was measured in control and patient sera by ELISA. An anti-D6-TNFR1-specific monoclonal Fab antibody was generated using HuCAL antibody technology (AbD Serotec) that uses a human combinatorial antibody library and the CysDisplay method of phage display. The anti-D6-TNFR1-specific antibody was coated onto Nunc microtitre plates at a concentration of 2 mg ml 21 overnight. The anti-human TNFR1 mouse monoclonal antibody (clone 16805; R&D Systems) was used at 2 mg ml 21 for detection, in conjunction with Europium-conjugated antimouse IgG. The sensitivity limit of the assay was determined to be ,1.25 ng ml 21 .
Recombinant protein expression, purification and TNF immunoprecipitation. HEK 293T cells were transiently transfected with TNF-Flag or F c fusion constructs. F c fusion proteins were purified from culture supernatant using protein A Sepharose (Sigma). Following F c -fusion protein pre-incubation with TNF-Flag, immunoprecipitation was performed using protein A Sepharose. An F c fusion of the first cysteine-rich domain of DR5 (DR5.CRD1-F c ) was used as a negative control for TNF binding. Tandem mass spectrometry. Purified D6-TNFR1-F c protein and transfected cell supernatants were solubilized and digested with chymotrypsin (Roche). The digested protein mixture was separated with a 140 min gradient from 5 to 60% acetonitrile (uHPLC, Proxeon) and loaded onto a LTQ-Orbitrap or a Q-Exactive mass spectrometer (Thermo Fisher). The instrument was operated in a datadependent top10 acquisition modus. Raw data were searched using the MaxQuant software suite (version 1.2.2.0) against the complete IPI human database (v3.68, 87061 entries) with an additional entry for the D6-TNFR1 isoform. The fragmentation spectra were plotted and annotated by the Viewer interface of MaxQuant. Surface plasmon resonance. Surface plasmon resonance spectroscopy was performed using the BIAcore T100 system. TNF-Flag was directly immobilized onto anti-Flag-coated chips from culture supernatants. Experiments were carried out using serial dilutions of the indicated purified F c -fusion proteins. Binding curves were analysed using BIAcore T100 Evaluation software to fit the data and determine dissociation constants (K d ), assuming 1:1 binding. TNF neutralization assay. Varying concentrations of purified F c fusion proteins ranging from 1-10,000 ng ml 21 were incubated with 5 3 10 4 HEK-Blue TNFa/IL-1b cells (InvivoGen) in the presence of 25 ng ml 21 of TNF. The assay was performed according to the manufacturer's instructions.
Statistical analysis of functional data. All statistical tests were performed using GraphPad Prism, GraphPad StatMate 2.0, and the R statistical software package. Regression analysis was used to test for correlations between rs1800693 genotype and TNFR1 transcript levels and TNFR1 cell surface expression in human immune cell subsets, assuming a linear genotype-to-phenotype relationship (1 degree of freedom F-test); age and sex were not included as covariates as for all data sets no age or sex effects were observed (P . 0.05). For the TNFR1_D6 transcripts the slope calculated by the linear regression analysis for the CD14 1 monocytes, polymorphonuclear cells and CD3 1 T cells was 0.0014, 0.0026 and 0.0003, respectively. Using a Bonferroni correction for multiple testing (taking P 5 0.05 and considering three independent hypotheses for the three different human immune cell subsets for RNA-level analyses), the significance threshold estimated was P 5 0.017. At this significance threshold we obtained .90% power to detect the differences observed with our sample size. The percentage of TNFR1_D6 transcript level variation accounted for by genotype at rs1800693 was estimated by least-squares regression analysis at 67, 52 and 55% for the CD14 1 monocytes, polymorphonuclear cells and CD3 1 T cells, respectively. Linear regression analysis was used to quantify the correlation in TNFR1_D6 transcript levels between the different immune cell subsets. For all regression analyses there was no significant departure from linearity (P . 0.05) as determined using a runs test. For the immune cell TNFR1 surface expression, using a Bonferroni correction (considering six independent hypotheses for six independent immune cell subsets), the significance threshold was P 5 0.008; at this threshold we had .80% power to detect a 50% difference between the homozygous groups, given our sample size. For the statistical analysis of the confocal colocalization quantification, two-tailed, paired Student's t-tests were performed. For all other analyses, two-tailed, unpaired Student's t-tests were performed. For all Student's t-tests a 5% significance threshold was used.
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